Showing 1-1 of 1 result
Pathway Directed Treatment for Refractory AML Consortium
Funded: 07-01-2013 through 06-30-2015
Funding Type: Consortium Research Grant
Institution Location: Phoenix, AZ
Institution: Phoenix Children's Hospital

Despite the toxic effects of current treatment for children and young adults with AML, overall survival remains poor because of recurrent leukemia. If their AML does not respond to chemotherapy after relapse, chances for survival are low. This team has identified important changes in AML that can be exploited to develop more effective and less toxic treatments using new types of drugs. The consortium focuses on showing that these pathways are needed for leukemia survival, and developing pathway-directed clinical trials to improve outcomes for this group of patients with no other treatment options. Funds administered by Phoenix Children's Hospital.